AR069904A1 - Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptables - Google Patents
Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptablesInfo
- Publication number
- AR069904A1 AR069904A1 ARP080105414A ARP080105414A AR069904A1 AR 069904 A1 AR069904 A1 AR 069904A1 AR P080105414 A ARP080105414 A AR P080105414A AR P080105414 A ARP080105414 A AR P080105414A AR 069904 A1 AR069904 A1 AR 069904A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorder
- depression
- dementia
- disease
- anxiety
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- 108010078791 Carrier Proteins Proteins 0.000 title 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 title 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010012289 Dementia Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 208000019901 Anxiety disease Diseases 0.000 abstract 4
- 230000036506 anxiety Effects 0.000 abstract 3
- 230000003542 behavioural effect Effects 0.000 abstract 3
- 208000010877 cognitive disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000036640 Asperger disease Diseases 0.000 abstract 2
- 201000006062 Asperger syndrome Diseases 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 2
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000012672 seasonal affective disease Diseases 0.000 abstract 2
- 208000019116 sleep disease Diseases 0.000 abstract 2
- 230000035882 stress Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010000117 Abnormal behaviour Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000009487 Amblyopia Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010011469 Crying Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000001836 Firesetting Behavior Diseases 0.000 abstract 1
- 206010017999 Gastrointestinal pain Diseases 0.000 abstract 1
- 206010064571 Gene mutation Diseases 0.000 abstract 1
- 206010020400 Hostility Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
- 102000004157 Hydrolases Human genes 0.000 abstract 1
- 108090000604 Hydrolases Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010022998 Irritability Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010070606 Post stroke depression Diseases 0.000 abstract 1
- 206010037213 Psychomotor retardation Diseases 0.000 abstract 1
- CVASBKDYSQKLSO-UHFFFAOYSA-N Tedatioxetine Chemical compound C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 CVASBKDYSQKLSO-UHFFFAOYSA-N 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 230000037328 acute stress Effects 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 208000025748 atypical depressive disease Diseases 0.000 abstract 1
- 208000026725 cyclothymic disease Diseases 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001544 dysphoric effect Effects 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 abstract 1
- 208000015046 intermittent explosive disease Diseases 0.000 abstract 1
- 206010023461 kleptomania Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 201000004645 pyromania Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 208000002271 trichotillomania Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un método para tratar una enfermedad seleccionada de retardo psicomotriz; depresion grave; trastorno distímico; ciclotimia; trastorno del humor debido a una afeccion médica generalizada; depresion inducida por sustancias; depresion recurrente; depresion de episodio unico; depresion pediátrica; depresion atípica; depresion post-accidente cerebrovascular; depresion por extenuacion; depresion asociada con dolor gastrointestinal, tal como lBS, abuso, hostilidad, irritabilidad, fatiga, ansiedad (depresion ansiosa), enfermedad de cuerpos de Lewy, enfermedad de Huntington, o esclerosis multiple; trastorno de ansiedad generalizada asociado con dolor; trastorno afectivo estacional (SAD); depresion o ansiedad en pacientes con mayor riesgo de hipertension; depresion o ansiedad en pacientes con problemas de sueno; trastorno relacionado con el estrés; estrés agudo; demencia; deterioro cognitivo leve (MCI); demencia vascular; leucariosis; enfermedad de vasos pequenos; deterioro cognitivo asociado con trastornos afectivos, depresion, depresion generalizada, trastorno depresivo grave, trastornos de ansiedad, trastorno de ansiedad generalizada, trastorno de pánico, trastorno obsesivo-compulsivo, esquizofrenia, enfermedad de Parkinson, demencia, demencia por SIDA, ADHD, deterioro de la memoria asociado con la edad, síndrome de Down, epilepsia, lesion cerebral traumática, síndrome de Asperger, y mutaciones del gen de triptofano hidrolasa; trastorno disforico pre-, peri- o post-menstrual; llanto patologico; autismo; obesidad; anorexia; bulimia; atracones; trastorno de control de impulsos; trastorno explosivo intermitente; cleptomanía; piromanía; juego patologico; tricotilomanía; trastorno de la conducta; burn-out; estrés; síndrome de fatiga cronica; trastorno del ritmo circadiano; trastorno del sueno; respiracion alterada por el sueno; síndrome de hipopnea; alteraciones de la conducta; alteraciones de la conducta en la tercera edad; alteraciones de la conducta asociadas con la demencia; trastorno compulsivo y del espectro de atencion asociado con ADHD, síndrome de Asperger y autismo; agresion y agitacion en la demencia y la enfermedad de Alzheimer; resistencia a la insulina asociada con hiperactividad del eje HPA; síndrome del latigazo (whiplash); miedo a volar, a los ascensores o a los espacios restringidos; y ambliopía, donde el método comprende la administracion de una cantidad terapéuticamente efectiva de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sales terapéuticamente aceptables de ésta (compuesto I) a un paciente que lo necesita. Reivindicacion 2: El método de acuerdo con la reivindicacion 1, en donde el compuesto I es cristalino, siempre que dicho compuesto no sea la sal del ácido clorhídrico. Reivindicacion 3: El método de acuerdo con la reivindicacion 1, en donde el compuesto I es la sal del ácido bromhídrico. Reivindicacion 4: El método de acuerdo con la reivindicacion 3, en donde el compuesto I es cristalino con picos de XRPD a aproximadamente 6,08, 14,81, 19,26 y 25,30 s2theta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701791 | 2007-12-14 | ||
| DKPA200701798 | 2007-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069904A1 true AR069904A1 (es) | 2010-03-03 |
Family
ID=40285887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105414A AR069904A1 (es) | 2007-12-14 | 2008-12-12 | Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptables |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20110053978A1 (es) |
| EP (1) | EP2231154A1 (es) |
| JP (1) | JP2011506353A (es) |
| KR (1) | KR20100092956A (es) |
| CN (1) | CN102202666A (es) |
| AR (1) | AR069904A1 (es) |
| AU (1) | AU2008338059A1 (es) |
| BR (1) | BRPI0819914A2 (es) |
| CA (1) | CA2708786A1 (es) |
| CL (1) | CL2008003709A1 (es) |
| CO (1) | CO6290669A2 (es) |
| EA (1) | EA201070737A1 (es) |
| IL (1) | IL205965A0 (es) |
| MX (1) | MX2010005795A (es) |
| NZ (1) | NZ586010A (es) |
| SG (1) | SG185984A1 (es) |
| TW (1) | TW200938194A (es) |
| WO (1) | WO2009076962A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE540941T1 (de) | 2006-06-16 | 2012-01-15 | Lundbeck & Co As H | 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen |
| TWI432194B (zh) * | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| GEP20166487B (en) * | 2010-04-30 | 2016-06-10 | Takeda Pharmaceutical | Enteric tablet |
| CN104710345B (zh) * | 2013-12-17 | 2017-09-05 | 江苏恩华药业股份有限公司 | 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用 |
| CN104120177A (zh) * | 2014-06-11 | 2014-10-29 | 杭州艾迪康医学检验中心有限公司 | 检测5-httlpr片段多态性的方法和引物 |
| WO2019008484A1 (en) * | 2017-07-03 | 2019-01-10 | Suven Life Sciences Limited | NEW USES OF A PURE 5-HT6 RECEPTOR ANTAGONIST |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DK1626720T3 (da) * | 2003-04-04 | 2008-12-01 | Lundbeck & Co As H | 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer |
| CA2656057C (en) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| TWI432194B (zh) * | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| HRP20140044T1 (hr) * | 2007-06-15 | 2014-02-14 | H. Lundbeck A/S | 4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs) |
-
2008
- 2008-12-02 TW TW097146699A patent/TW200938194A/zh unknown
- 2008-12-11 CA CA2708786A patent/CA2708786A1/en not_active Abandoned
- 2008-12-11 CN CN2008801203913A patent/CN102202666A/zh active Pending
- 2008-12-11 MX MX2010005795A patent/MX2010005795A/es not_active Application Discontinuation
- 2008-12-11 BR BRPI0819914A patent/BRPI0819914A2/pt not_active IP Right Cessation
- 2008-12-11 US US12/747,403 patent/US20110053978A1/en not_active Abandoned
- 2008-12-11 AU AU2008338059A patent/AU2008338059A1/en not_active Abandoned
- 2008-12-11 KR KR1020107013095A patent/KR20100092956A/ko not_active Withdrawn
- 2008-12-11 WO PCT/DK2008/050302 patent/WO2009076962A1/en not_active Ceased
- 2008-12-11 EP EP08862439A patent/EP2231154A1/en not_active Withdrawn
- 2008-12-11 EA EA201070737A patent/EA201070737A1/ru unknown
- 2008-12-11 JP JP2010537257A patent/JP2011506353A/ja active Pending
- 2008-12-11 SG SG2012083010A patent/SG185984A1/en unknown
- 2008-12-11 NZ NZ586010A patent/NZ586010A/xx not_active IP Right Cessation
- 2008-12-12 CL CL2008003709A patent/CL2008003709A1/es unknown
- 2008-12-12 AR ARP080105414A patent/AR069904A1/es not_active Application Discontinuation
-
2010
- 2010-05-25 IL IL205965A patent/IL205965A0/en unknown
- 2010-06-11 CO CO10070917A patent/CO6290669A2/es not_active Application Discontinuation
-
2014
- 2014-05-16 US US14/279,504 patent/US20140296290A1/en not_active Abandoned
-
2016
- 2016-05-03 US US15/145,102 patent/US20170087138A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009076962A1 (en) | 2009-06-25 |
| NZ586010A (en) | 2012-08-31 |
| US20110053978A1 (en) | 2011-03-03 |
| JP2011506353A (ja) | 2011-03-03 |
| US20140296290A1 (en) | 2014-10-02 |
| CO6290669A2 (es) | 2011-06-20 |
| TW200938194A (en) | 2009-09-16 |
| CA2708786A1 (en) | 2009-06-25 |
| CL2008003709A1 (es) | 2010-01-15 |
| EP2231154A1 (en) | 2010-09-29 |
| AU2008338059A1 (en) | 2009-06-25 |
| US20170087138A1 (en) | 2017-03-30 |
| SG185984A1 (en) | 2012-12-28 |
| IL205965A0 (en) | 2010-11-30 |
| MX2010005795A (es) | 2010-08-31 |
| EA201070737A1 (ru) | 2010-12-30 |
| KR20100092956A (ko) | 2010-08-23 |
| BRPI0819914A2 (pt) | 2016-05-17 |
| CN102202666A (zh) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069260A1 (es) | Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. | |
| US20250099459A1 (en) | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof | |
| Bah et al. | Sleep as a therapeutic target in the aging brain | |
| AR069904A1 (es) | Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptables | |
| Bassetti et al. | REM sleep behavior disorder | |
| WO2021139874A1 (en) | Cognitive disorder prevention and therapy | |
| ES2206400T3 (es) | Utilizacion de modafinilo para la preparacion de un medicamento destinado a corregir los trastornos de la vigilia asociados a las miopatias. | |
| Armocida et al. | The acetylcholine therapy in the treatment of schizophrenia–the experience of Mario Fiamberti in the Hospital of Varese (1937) | |
| JP2008519056A5 (es) | ||
| FI4263517T3 (fi) | Substituoitu tetrahydroisokinoliinijohdannainen d1-positiivisena allosteerisenä modulaattorina | |
| JPWO2021001288A5 (es) | ||
| Lee et al. | Amyotrophic lateral sclerosis with an acute hypertensive crises | |
| JP7773909B2 (ja) | 筋痛性脳脊髄炎／慢性疲労症候群治療剤 | |
| RU2825336C2 (ru) | Кетамин памоат и его применение | |
| Lavoie et al. | The role of cholinergic signaling in multi-sensory gamma stimulation induced perivascular clearance of amyloid | |
| RU2010120846A (ru) | Соединения 2,3-дигидробензофурана, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| Hellwig | Effect of subthalamic stimulation on mood state in Parkinson’s disease: evaluation of previous facts and problems | |
| RU2022101512A (ru) | Замещенное производное тетрагидроизохинолина, как позитивный аллостерический модулятор d1 | |
| KR102161787B1 (ko) | 수면 장애의 예방 또는 치료용 약학적 조성물 | |
| US20180177748A1 (en) | Combination medication for neuro-degenerative diseases | |
| HK40046879A (en) | Prophylactic and/or therapeutic agent containing brexpiprazole or salt thereof | |
| HK40077419A (en) | Prophylactic and/or therapeutic agent containing brexpiprazole or salt thereof | |
| McCarter et al. | Sleep, Cognitive Dysfunction, and Dementia | |
| Vgenopoulou et al. | Melatonin levels in Alzheimer disease | |
| Khaddafi et al. | A Case Series from Rantauprapat, La Belle Indifference: A Coping Mechanism or Is There Something Organic Behind? Open Access Maced Med Sci. 2019 Aug 30; 7 (16): 2675-2678 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |